DeepHealth, RadNet’s Digital Health division, delivered record quarterly revenue, strong commercial momentum and continued expansion of its integrated AI-powered health informatics portfolio, contributing to RadNet’s record second-quarter 2026 financial results.
RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 owned and operated outpatient imaging centers, reported Total Company Revenue of $622.7 million for the second quarter of 2026. Revenue increased 25.0% from $498.2 million in the second quarter of 2025. Total Company Adjusted EBITDA was a quarterly record of $99.7 million, an increase of 22.7% compared with the prior-year quarter.
DeepHealth’s Revenue increased 56.5% year over year to $32.4 million in the second quarter of 2026. At June 30, 2026, Annual Recurring Revenue (ARR)* was $105.5 million, an increase of 97.2% from June 30, 2025 and an increase of 8.9% sequentially from March 31, 2026. ARR generated by non- RadNet customers now comprises approximately 63% of its Revenue.
During the second quarter, DeepHealth signed new business with Total Contract Value of approximately $21 million, split about evenly between North America and Europe and rest of the world, bringing its six-month new business Total Contract Value to approximately $37 million. The majority of new business is with hospitals and health systems and spans the full breadth of DeepHealth’s portfolio.
“Our strong Q2 performance reflects the distinct value of DeepHealth as the partner bringing Clinical AI, Enterprise Imaging and Imaging Operations together on one platform to transform the radiology workflow,” said Kees Wesdorp, CEO of RadNet’s Digital Health division, DeepHealth. “By embedding clinical and operational intelligence across the imaging journey, we aim to automate radiology, guide patient journeys, accelerate acute care, and stage shift disease. This is how we are advancing a new standard of care.”
DeepHealth’s customer base has scaled to nearly 3,000 accounts and further expanded its portfolio to now include 27 FDA-cleared and 26 CE-marked devices supporting more than 100 indications. Total procedure volume managed exceeded 17 million during the quarter, increasing more than 200% year over year and reflecting both organic growth and the scale added through recent acquisitions. Following the acquisition of Gleamer in March 2026, organizational integration is complete, and product roadmaps have been merged.
DeepHealth Adjusted EBITDA was $2.5 million for the quarter, compared with $3.4 million in the second quarter of 2025. The year-over-year decrease reflects deliberate investments in DeepHealth’s commercial, service and implementation organizations to fuel growth.
RadNet reaffirmed all DeepHealth (Digital Health reportable segment) guidance ranges, including full-year Revenue of $135 million to $145 million and Adjusted EBITDA of $10 million to $12 million. DeepHealth also remains on track to exceed $140 million in ARR by year-end.
Read the RadNet Q2 2026 earning release here and watch the recording of RadNet’s earnings call here.
—-
* We use Annual Recurring Revenue (“ARR”) as a key operating metric to evaluate the scale, growth and health of the recurring component of our Digital Health business. We define ARR as a key subscription-economy metric representing the predictable, normalized annualized value of contracted recurring revenue generated from active customer contracts. ARR includes subscription fees, recurring support fees and contracted usage charges, and excludes one-time or non-recurring fees, such as implementation fees, hardware sales, professional services, consulting and one-time training. ARR is determined based on the contractual terms of active customer arrangements and is not calculated by reference to revenue recognized under GAAP, deferred revenue or another GAAP financial measure. Accordingly, ARR is an operating metric and not a non-GAAP financial measure. ARR should be viewed independently of revenue and deferred revenue and is not intended to be combined with, or to replace, either measure. ARR is not a forecast of future revenue, which may be affected by contract start and end dates, cancellations, renewal rates, customer usage and other factors. ARR does not have a standardized definition and may not be comparable to similarly titled measures presented by other companies.
